A 2-week Nitazoxanide-based quadruple treatment as a rescue therapy for Helicobacter pylori eradication: A single center experience

Sherief Abd-Elsalam, Abdelrahman Kobtan, Ferial El-Kalla, Walaa Elkhalawany, Sally El Nawasany, Sabry Abou Saif, Mohamed Yousef, Lobna Abo Ali, Samah Soliman, Loai Mansour, Eslam Habba, Hanan Soliman, Fatma Rizk, Mona Ah Shehata, Sherief Abd-Elsalam, Abdelrahman Kobtan, Ferial El-Kalla, Walaa Elkhalawany, Sally El Nawasany, Sabry Abou Saif, Mohamed Yousef, Lobna Abo Ali, Samah Soliman, Loai Mansour, Eslam Habba, Hanan Soliman, Fatma Rizk, Mona Ah Shehata

Abstract

As there are increasing reports of fluoroquinolone resistance on use as a first- or second-line treatment for Helicobacter pylori (H pylori), we aimed at evaluation of the efficacy and safety of nitazoxanide-based regimen as a rescue regimen in Egyptian patients whose previous traditional treatment for H pylori infection failed.In total, 100 patients from the outpatient clinic of the Tropical medicine department, Tanta University hospital in whom the standard triple therapy (clarithromycin-based triple therapy) failed were enrolled in the study. Nitazoxanide (500 mg bid), levofloxacin (500 mg once daily), omeprazole (40 mg bid), and doxycyclin (100 mg twice daily) were prescribed for 14 days. Eradication was confirmed by stool antigen for H pylori 6 weeks after the end of treatment. Among the patients enrolled in the study, 44% of patients were men and the mean age for the participants in the study was 46.41 ± 8.05, 13% of patients were smokers, and 4% of patients had a previous history of upper gastro-intestinal bleeding. A total of 94 patients (94%) completed the study with excellent compliance. Only 1 patient (1%) discontinued treatment due to intolerable side effects and 5 patients (5%) did not achieve good compliance or were lost during follow up. However, 83 patients had successful eradication of H pylori with total eradication rates 83% (95 % CI 75.7-90.3%) and 88.30% (95 % CI 81.8-94.8%) according to an intention-to-treat and per-protocol analysis, respectively. Adverse events were reported in 21% of patients: abdominal pain (6%), nausea (9%) and constipation (12%), (2%) headache, and (1%) dizziness. A 2-week nitazoxanide-based regimen is an effective and safe rescue therapy in Egyptian patients whose previous standard triple therapy has failed.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Flow diagram of quadruple therapy.

References

    1. Graham DY. Benefits from elimination of Helicobacter pylori infection include major reduction in the incidence of peptic ulcer disease, gastric cancer, and primary gastric lymphoma. Prev Med 1994;23:712–6.
    1. Peek MR, Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28–37.
    1. Malfertheiner P, Mégraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection—the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167–80.
    1. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;194:409–14.
    1. Gisbert JP, González L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000;14:1319–28.
    1. Stenström B, Mendis A, Marshall B. Helicobacter pylori—the latest in diagnosis and treatment. Aust Fam Physician 2008;37:608.
    1. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;263:343–57.
    1. Graham DY, Shiotani A. Newer concepts regarding resistance in the treatment Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008;56:321.
    1. Hsu PI, Wu DC, Chen A, et al. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures. Eur J Clin Invest 2008;38:404–9.
    1. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587.
    1. Hojo M, Miwa H, Nagahara A, et al. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690–700.
    1. Chey WD, Wong BCY. Practice Parameters Committee of the American College of Gastroenterology. Management of Helicobacter pylori Infection. Am J Gastroenterol 2007;102:1808–25.
    1. Dore MP, Marras L, Maragkoudakis E, et al. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003;8:307–9.
    1. Zullo A, De Francesco V, Manes G, et al. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;192:131–4.
    1. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62:34–2.
    1. Liou JM, Bair MJ, Chen CC, et al. Levofloxacin sequential therapy vs levofloxacin triple therapy in the second-line treatment of Helicobacter pylori: a randomized trial. Am J Gastroenterol 2016;1113:381–7.
    1. Liang CM, Cheng JW, Kuo CM, et al. Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice. Biomed J 2014;375:326–0.
    1. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;6713:1947–67.
    1. Guttner Y, Windsor HM, Viiala CH, et al. Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study. Antimicrob Agents Chemother 2003;4712:3780.
    1. Basu PP, Rayapudi K, Pacana T, et al. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am J Gastroenterol 2011;106:1970–5.
    1. Parashar UD, Hummelman EG, Bresee JS, et al. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003;9:565–72.
    1. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597–604.
    1. Arya SC. Nitazoxanide as a broad-spectrum antiparasitic agent. J Infect Dis 2002;185:1692.
    1. Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998;4211:2836–40.
    1. Ramos–Soriano AG, Black J. Nitazoxanide use as part of an empiric multi-drug regimen in treating children with suspected Helicobacter pylori infection. Gastroenterol 2015;9:36–42.
    1. Walker RC. Symposium on antimicrobial agents-part XIII: the fluoroquinolones. Mayo Clin Proc 1991;74:1030–7.
    1. Di Caro S, Franceschi F, Mariana A, et al. Second line levofloxacin based triple schemes for Helicobacter pylori eradication. Dig Liver Dis 2009;41:480–5.
    1. Smilack JD. Symposium on anti microbial agents. part 10: the tetracyclines. Mayo Clin Proc 1999;74:727–9.
    1. Duck MW, Sobel J, Pe-ruckler JM, et al. Anti microbial resistance incidence and risk factors among H pylori-infected persons, United States. Emerg Infec Dis 2004;10:1088–94.
    1. Gisbert JP, Pajares JM. Review article: Helicobacter pylori ‘rescue’ regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047–57.
    1. Romano M, Lovene MR, Russo MI, et al. Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates. J Clin Pathol 2008;61:1112–5.
    1. Carothers JJ, Bruce MG, Hennessy TW, et al. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007;44:e5–8.
    1. Molina-Infante J, Lucendo AJ, Angueira T, et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. Aliment Pharmacol Ther 2015;41:581–9.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj